Archive

Inhibition studies to direct oral immunotherapy in walnut-hazelnut co-allergic patients (nut CRACKER study).

Koren, Y., M.Y. Appel, M. Elkan, L. Nachshon, L. Mattsson, J. Lidholm, M.B. Levy, A. Elizur, M.R. Goldberg, 2026. Inhibition studies to direct oral immunotherapy in walnut-hazelnut co-allergic patients (nut CRACKER study). Pediatr Allergy Immunol. 37:e70500. doi:10.1111/pai.70500

Background: Walnut OIT has been observed to induce cross-desensitization to hazelnut, but predictors of this response remain unclear. We sought to identify molecular predictors of hazelnut cross-desensitization following walnut OIT, to help guide treatment decisions in these co-allergic patients. Methods: Patients with confirmed IgE-mediated walnut and hazelnut allergy underwent walnut OIT. Patients achieving full walnut desensitization to 4 g of walnut protein were re-challenged to 4-grams hazelnut protein after 6 months. Baseline sera were obtained and competitive ELISA inhibition assays performed to evaluate serum IgE cross-recognition of total walnut, total hazelnut and hazelnut component-specific IgE. Results were compared between patients fully (4-grams protein) or clinically (≥30-fold ED increase or mild reaction at full dose) cross-desensitized to hazelnut and those who remained hazelnut allergic following walnut OIT. Results: Overall, 12/22 (54.5%) patients were fully cross-desensitized, and 14/22 (63.6%) patients were clinically cross-desensitized to hazelnut following walnut OIT. Among the latter, walnut inhibited total hazelnut-specific IgE binding by a median of 95%, compared to 55% in those who remained hazelnut allergic (p < .01). Similarly, walnut extract competed for IgE binding to hazelnut components Cor a 9 (p = .003) and Cor a 16 (p = .023) in the cross-desensitized group following walnut OIT, but not in the persistent hazelnut allergic group. A ≥70% inhibition threshold accurately predicted cross-desensitization in 93% of cases (p < .001). Conclusion: Walnut OIT can induce clinical cross-desensitization to hazelnut in >60% of co-allergic individuals. Competitive ELISA inhibition is a promising predictive tool, with potential to guide targeted and efficient OIT strategies in walnut-hazelnut co-allergic patients.

The role of peanuts and tree nuts in improving diet and sleep quality: A pilot study and literature review.

Tindall, A., M.C. Kissell, 2026. The role of peanuts and tree nuts in improving diet and sleep quality: A pilot study and literature review. 18(4):579. doi: 10.3390/nu18040579.

Background: Peanuts and tree nuts are nutrient-dense foods associated with improved diet quality and reduced chronic disease risk. Diet quality and sleep are interrelated, but the relationship between nut consumption and sleep quality remains understudied, particularly among young adults. Objective: This study examined peanut and tree nut consumption, diet quality, and sleep quality in undergraduate students. Existing clinical trials on nut intake and sleep outcomes in healthy adults were reviewed. Methods: A pilot study recruited 46 undergraduates to complete three 24 h dietary recalls and self-report sleep quality. Recall days were categorized as containing nuts or no nuts. Diet quality was assessed using the Healthy Eating Index-2020 (HEI). A literature search of PubMed identified human clinical trials testing nut intake with sleep-related outcomes. Results: Sixteen percent of the 139 recall days contained nuts. Mean HEI scores were greater on days that contained nuts (64.9 ± 2.3) versus nut-free days (45.4 ± 1.1; p < 0.0001). Scores for total fruit, whole fruit, total protein, sea and plant protein, sodium, and refined grains were greater on nut-containing days (p < 0.05 for all). Participants reported better sleep on days following nut consumption (p = 0.04). From the literature search, four randomized controlled trials (RCTs) were identified with results varying by nut type, dosage, timing, and participants. Conclusions: The positive association observed in this pilot study between nut intake and improved diet quality, along with a modest link to better sleep quality, suggests that incorporating nuts regularly into the diet may help enhance overall dietary habits and contribute to improved sleep. The present trials suggest nut intake may improve sleep quality, but significant heterogeneity highlights the need for RCTs with objective sleep outcomes.

Urolithins from walnuts are associated with cognitive performance: ancillary results from the Walnuts and Healthy Aging (WAHA) randomized trial.

Galkina, P., I. Domínguez-López, M. Cofán, C. Pozzoli, O. Jáuregui, C. Abarca-Rivas, M. Corrado, A. Vallverdú-Queralt, M. Serra-Mir, G. Chiva-Blanch, S. Rajaram, J. Sabaté, A. Sala-Vila, E. Ros, R.M. Lamuela-Raventós, 2026. Urolithins from walnuts are associated with cognitive performance: ancillary results from the Walnuts and Healthy Aging (WAHA) randomized trial. Food Science and Human Wellness. doi: https://doi.org/10.26599/FSHW.2026.9251028.

Urolithins, microbiota-derived metabolites of ellagitannins, phenolic compounds abundant in walnuts, possess anti-inflammatory and antioxidant properties that might mitigate neuronal damage. However, clinical data supporting their effects on cognition are limited. In participants in the Walnuts and Healthy Aging (WAHA) trial, we determined urinary urolithin concentrations and examined their association with cognitive performance. The WAHA study was a parallel-group, 2-center (Barcelona, Spain; Loma Linda, California), randomized controlled trial. Cognitively healthy individuals followed a 2-year walnut-rich diet (15% daily energy) or a control diet excluding walnuts. Baseline and 2-year determinations included urinary urolithins by liquid chromatography-mass spectrometry and a comprehensive neuropsychological battery. The primary outcome was the association between changes in a global cognition composite score and urinary urolithins as the exposure, assessed by multivariable-adjusted regression. Secondary outcomes included associations of urolithins with domain-specific changes in memory, language, perception, and frontal function. A total of 612 participants (66% women, mean age 69 y) were included in analyses. Urolithin A, urolithin C and their glucuronide forms were objective biomarkers of walnut consumption (area under the curve at receiver operator characteristic analysis, 0.83; 95% CI, 0.80-0.86, 0.78; 95% CI, 0.74-0.82, 0.81; 95% CI, 0.77-0.84, and 0.80; 95% CI, 0.76-0.83, respectively). In the WAHA cohort following the walnut diet, changes in urolithin A glucuronide (β = 0.014 [95% CI, 0.003-0.025] per 1-SD) and urolithin C (β = 0.017 [95% CI, 0.001-0.033] per 1-SD) were associated with concurrent changes of the global cognition score. Urinary urolithins, particularly UroA, UroC and their glucuronides, are reliable biomarkers of walnut consumption. Changes in urolithin levels after 2 years of daily walnut consumption disclosed a direct association with cognitive performance in cognitively healthy older individuals. These findings provide clinical evidence linking dietary (poly)phenols and cognitive health.

Microbiota-derived urolithins and cortical thickness in cognitively healthy older adults: a longitudinal MRI analysis of the WAHA trial.

Galkina, P., I. Domínguez-López, M. Cofán, C. Pozzoli, A. Vallverdú-Queralt, M. Serra-Mir, G. Chiva-Blanch, S. Rajaram, J. Sabaté, A. Sala-Vila, E. Ros, R.M. Lamuela-Raventós, 2026. Microbiota-derived urolithins and cortical thickness in cognitively healthy older adults: a longitudinal MRI analysis of the WAHA trial. Food & Function. doi: https://doi.org/10.1039/D6FO02116F.

Background & aims: Walnuts are nutrient-dense foods rich in bioactive compounds that may support mental health. However, evidence linking walnut consumption to mood regulation and to changes in urinary metabolites potentially associated with these effects in humans remains limited. This randomized crossover trial (RCT) aimed to evaluate the effects of an 8-week walnut (Juglans regia) intervention on mood states in young adults and to explore the potential mechanistic links through urinary serotonin metabolite (5-hydroxyindoleacetic acid, 5-HIAA), cortisol, and urolithins. Methods: In this 18-week open-label RCT, 31 healthy young adults (mean age 24.0 ± 4.2 years; 90.3% female) consumed 40 g per day of walnuts for 8 weeks (intervention) and followed a nut-free control period of equal length, separated by a 2-week washout. Mood states, perceived stress, well-being, and trait food cravings were assessed using validated questionnaires. Urinary concentrations of 5-HIAA and cortisol were quantified via ELISA and normalized to creatinine. Walnut-derived urolithins were determined in urine samples as biomarkers of intake by HPLC-QTOF-MS. Linear mixed-effects models were used to test differences in outcome variables between intervention and control conditions, and repeated-measures correlations were performed to assess within-individual associations between the outcome variables. Results: Compared to the control condition, the 8-week walnut intervention significantly reduced total mood disturbance scores (−4.85 points, p = 0.030). In addition, the walnut intervention significantly increased urinary 5-HIAA levels, with no changes in urinary cortisol. Increases in urinary 5-HIAA were significantly associated with reductions in fatigue (r = –0.392, p = 0.031) and total mood disturbance (r = –0.362, p = 0.049). Urinary levels of urolithins significantly increased during the intervention and were strongly correlated with concurrent changes in urinary 5-HIAA (r = 0.537 and r = 0.634, respectively). Conclusions: Daily walnut consumption improved total mood disturbance scores in young adults. These findings were accompanied by increased urinary 5-HIAA and urolithin levels. The concurrent changes in these urinary metabolites may reflect dietary, microbial, or peripheral metabolic responses to walnut consumption; however, mechanistic pathways warrant further investigation. These findings highlight the relevance of whole-food strategies in nutritional approaches to mental health.